Related Experiment Video
Updated: Nov 23, 2025
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
The prospects of tumor chemosensitivity testing at the single-cell level
Chuan Yang1, Caibo Yang2, Yosef Yarden3
1State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.
Abstract:
Tumor chemosensitivity testing plays a pivotal role in the optimal selection of chemotherapeutic regimens for cancer patients in a personalized manner. High-throughput drug screening approaches have been developed but they failed to take into account intratumor heterogeneity and therefore only provided limited predictive power of therapeutic response to individual cancer patients. Single cancer cell drug sensitivity testing (SCC-DST) has been recently developed to evaluate the variable sensitivity of single cells to different anti-tumor drugs. In this review, we discuss how SCC-DST overcomes the obstacles of traditional drug screening methodologies. We outline critical procedures of SCC-DST responsible for single-cell generation and sorting, cell-drug encapsulation on a microfluidic chip and detection of cell-drug interactions. In SCC-DST, droplet-based microfluidics is emerging as an important platform that integrated various assays and analyses for drug susceptibility tests for individual patients. With the advancement of technology, both fluorescence imaging and label-free analysis have been used for detecting single cell-drug interactions. We also discuss the feasibility of integrating SCC-DST with single-cell RNA sequencing to unravel the mechanisms leading to drug resistance, and utilizing artificial intelligence to facilitate the analysis of various omics data in the evaluation of drug susceptibility. SCC-DST is setting the stage for better drug selection for individual cancer patients in the era of precision medicine.
Insights
Single cancer cell drug sensitivity testing (SCC-DST) offers personalized chemotherapy selection by assessing individual cell responses. This advanced method overcomes limitations of traditional screening for improved cancer treatment outcomes.
Area of Science:
- Oncology
- Biotechnology
- Microfluidics
Background:
- Personalized cancer therapy relies on accurate tumor chemosensitivity testing.
- Traditional high-throughput drug screening fails to address intratumor heterogeneity, limiting predictive accuracy.
- Single cancer cell drug sensitivity testing (SCC-DST) emerged to evaluate drug sensitivity at the single-cell level.
Purpose of the Study:
- To review the methodologies and advancements in single cancer cell drug sensitivity testing (SCC-DST).
- To highlight how SCC-DST overcomes limitations of conventional drug screening approaches.
- To discuss the potential of SCC-DST in precision medicine for improved cancer treatment selection.
Main Methods:
- Detailed outline of SCC-DST procedures, including single-cell isolation, sorting, and microfluidic-based cell-drug encapsulation.
- Discussion of detection methods for single cell-drug interactions, including fluorescence imaging and label-free analysis.
- Exploration of integrating SCC-DST with single-cell RNA sequencing and artificial intelligence for mechanism elucidation and data analysis.
Main Results:
- SCC-DST provides a more accurate assessment of drug sensitivity by considering intratumor heterogeneity.
- Droplet-based microfluidics serves as a key platform for integrated SCC-DST assays.
- Advanced detection techniques enable robust analysis of single cell-drug interactions.
Conclusions:
- SCC-DST represents a significant advancement over traditional methods for evaluating cancer drug sensitivity.
- The integration of SCC-DST with omics technologies and AI promises deeper insights into drug resistance mechanisms.
- SCC-DST is poised to revolutionize drug selection for individual cancer patients in the era of precision medicine.
